[8-K] P10, Inc. Reports Material Event
P10, Inc. reported that it entered into interest-rate derivative arrangements tied to its Amended and Restated Credit Agreement dated August 1, 2024. The company sold a 3‑month term SOFR floor at 2.310% and purchased a cap at 4.250% on a notional amount of $211,250,000. The filing states these instruments were executed to manage the variable interest-rate risk associated with borrowings under the credit facility. The disclosure is signed by Amanda Coussens, Chief Financial Officer, and dated September 18, 2025.
P10, Inc. ha riferito di aver stipulato accordi derivati sui tassi di interesse legati al proprio Amended and Restated Credit Agreement datato 1 agosto 2024. L'azienda ha venduto una floor SOFR a termine di 3 mesi al 2,310% e ha acquistato un cap al 4,250% su un importo nozionale di $211,250,000. La comunicazione afferma che tali strumenti sono stati eseguiti per gestire il rischio variabile di tasso di interesse associato ai prestiti ai sensi della linea di credito. La disclosure è firmata da Amanda Coussens, Chief Financial Officer, e datata 18 settembre 2025.
P10, Inc. informó que celebró acuerdos derivados sobre tasas de interés vinculados a su Amended and Restated Credit Agreement con fecha del 1 de agosto de 2024. la compañía vendió una floor SOFR a plazo de 3 meses al 2,310% y compró un cap al 4,250% sobre un monto nocional de $211,250,000. La presentación indica que estos instrumentos se ejecutaron para gestionar el riesgo de tasa de interés variable asociado a los préstamos bajo la facility de crédito. La divulgación está firmada por Amanda Coussens, Directora Financiera, y fechada el 18 de septiembre de 2025.
P10, Inc.가 2024년 8월 1일자로 개정 및 재작성된 신용계약(Amended and Restated Credit Agreement)과 연계된 금리 파생상품 계약을 체결했다고 발표했습니다. 회사는 3개월 만기 SOFR 바닥금리 2.310%를 매도하고 상한금리 4.250%를 매입했으며, 명시액은 $211,250,000입니다. 제출 자료에는 이러한 도구가 신용시설 대출에 수반되는 가변 금리 위험을 관리하기 위해 실행되었음이 명시되어 있습니다. 이 공시는 최고재무책임자(CFO)인 Amanda Coussens가 서명했으며 날짜는 2025년 9월 18일입니다.
P10, Inc. a annoncé avoir conclu des accords dérivés de taux d'intérêt liés à son Amended and Restated Credit Agreement daté du 1er août 2024. La société a vendu une floor SOFR à terme de 3 mois à 2,310% et acheté un cap à 4,250% sur un montant notionnel de $211 250 000. Le dossier indique que ces instruments ont été exécutés pour gérer le risque de taux d'intérêt variable associé aux emprunts sous la facilité de crédit. La divulgation est signée par Amanda Coussens, Directrice financière, et datée du 18 septembre 2025.
P10, Inc. gab bekannt, dass es Zinssatz-Derivate abgeschlossen hat, die mit seinem amendierten und neu geordneten Kreditvertrag vom 1. August 2024 verbunden sind. Das Unternehmen verkaufte eine 3-Monats-SOFR-Floor-Lieferung bei 2,310% und kaufe eine Cap bei 4,250% auf einen Nominalbetrag von $211.250.000. Die Einreichung besagt, dass diese Instrumente zur Steuerung des variablen Zinsrisikos in Verbindung mit den Darlehen unter der Kreditfazilität ausgeführt wurden. Die Offenlegung ist von Amanda Coussens, Chief Financial Officer, unterschrieben und auf den 18. September 2025 datiert.
P10, Inc. أبلغت عن دخول ترتيبات مشتقات سعر الفائدة المرتبطة باتفاقها الائتماني المعدل والمراجع بتاريخ 1 أغسطس 2024. قامت الشركة ببيع floor SOFR لمدة ثلاثة أشهر عند 2.310% و شراء cap عند 4.250% على مبلغ اسمّي قدره $211,250,000. وتذكر الإفادة أن هذه الآلات أُنفِذت لإدارة مخاطر سعر الفائدة المتغيرة المرتبطة بالاقتراضات بموجب تسهيلات الائتمان. وتوقيع الإفصاح من قبل Amanda Coussens، المدير المالي، وتاريخ 18 سبتمبر 2025.
P10, Inc. 报告称，其就其经修订并更名的信贷协议（Amended and Restated Credit Agreement）签订了与利率相关的衍生工具安排，日期为 2024 年 8 月 1 日。公司 以 3 个月期 SOFR 下限期出售，以 4.250%购买一个上限，名义金额为 $211,250,000。文件显示这些工具的执行是为了管理与信用设施下 borrowing 相关的可变利率风险。披露由首席财务官 Amanda Coussens 签署，日期为 2025 年 9 月 18 日。
- Established interest-rate hedges covering a material notional of $211,250,000 to address borrowing rate volatility
- Clear alignment of the derivatives with the company’s Amended and Restated Credit Agreement dated August 1, 2024
- Documented counterparty and agent bank roles including JPMorgan Chase Bank, N.A. as administrative and collateral agent
- None.
Insights
TL;DR: Company established $211.25M SOFR-linked hedges to manage variable borrowing costs under its credit facility.
The filing documents a straightforward hedging trade: sale of a 3-month SOFR floor at 2.310% and purchase of a 4.250% cap on a $211,250,000 notional. This structure indicates the company is taking explicit steps to limit exposure to rising short-term SOFR while exchanging certain rate-floor economics. The instruments are linked to the Amended and Restated Credit Agreement dated August 1, 2024, which aligns the hedge with the company’s borrowing profile. Disclosure is concise and factual, without performance metrics or valuation details.
TL;DR: The derivatives appear designed to manage interest-rate volatility on outstanding credit facility borrowings.
The positions—selling a 2.310% SOFR floor and buying a 4.250% cap—are explicitly described as risk-management actions for variable-rate borrowings under the company’s credit agreement. The filing provides notional size but does not disclose hedge accounting treatment, counterparty details beyond agent banks, or mark-to-market exposures. The lack of valuation and counterparty specifics limits assessment of counterparty concentration and balance-sheet effects.
P10, Inc. ha riferito di aver stipulato accordi derivati sui tassi di interesse legati al proprio Amended and Restated Credit Agreement datato 1 agosto 2024. L'azienda ha venduto una floor SOFR a termine di 3 mesi al 2,310% e ha acquistato un cap al 4,250% su un importo nozionale di $211,250,000. La comunicazione afferma che tali strumenti sono stati eseguiti per gestire il rischio variabile di tasso di interesse associato ai prestiti ai sensi della linea di credito. La disclosure è firmata da Amanda Coussens, Chief Financial Officer, e datata 18 settembre 2025.
P10, Inc. informó que celebró acuerdos derivados sobre tasas de interés vinculados a su Amended and Restated Credit Agreement con fecha del 1 de agosto de 2024. la compañía vendió una floor SOFR a plazo de 3 meses al 2,310% y compró un cap al 4,250% sobre un monto nocional de $211,250,000. La presentación indica que estos instrumentos se ejecutaron para gestionar el riesgo de tasa de interés variable asociado a los préstamos bajo la facility de crédito. La divulgación está firmada por Amanda Coussens, Directora Financiera, y fechada el 18 de septiembre de 2025.
P10, Inc.가 2024년 8월 1일자로 개정 및 재작성된 신용계약(Amended and Restated Credit Agreement)과 연계된 금리 파생상품 계약을 체결했다고 발표했습니다. 회사는 3개월 만기 SOFR 바닥금리 2.310%를 매도하고 상한금리 4.250%를 매입했으며, 명시액은 $211,250,000입니다. 제출 자료에는 이러한 도구가 신용시설 대출에 수반되는 가변 금리 위험을 관리하기 위해 실행되었음이 명시되어 있습니다. 이 공시는 최고재무책임자(CFO)인 Amanda Coussens가 서명했으며 날짜는 2025년 9월 18일입니다.
P10, Inc. a annoncé avoir conclu des accords dérivés de taux d'intérêt liés à son Amended and Restated Credit Agreement daté du 1er août 2024. La société a vendu une floor SOFR à terme de 3 mois à 2,310% et acheté un cap à 4,250% sur un montant notionnel de $211 250 000. Le dossier indique que ces instruments ont été exécutés pour gérer le risque de taux d'intérêt variable associé aux emprunts sous la facilité de crédit. La divulgation est signée par Amanda Coussens, Directrice financière, et datée du 18 septembre 2025.
P10, Inc. gab bekannt, dass es Zinssatz-Derivate abgeschlossen hat, die mit seinem amendierten und neu geordneten Kreditvertrag vom 1. August 2024 verbunden sind. Das Unternehmen verkaufte eine 3-Monats-SOFR-Floor-Lieferung bei 2,310% und kaufe eine Cap bei 4,250% auf einen Nominalbetrag von $211.250.000. Die Einreichung besagt, dass diese Instrumente zur Steuerung des variablen Zinsrisikos in Verbindung mit den Darlehen unter der Kreditfazilität ausgeführt wurden. Die Offenlegung ist von Amanda Coussens, Chief Financial Officer, unterschrieben und auf den 18. September 2025 datiert.
FAQ
What hedging instruments did P10, Inc. (PX) enter into?
What is the purpose of P10's SOFR floor and cap transactions?
Which credit agreement are the hedges linked to for P10 (PX)?
What is the notional amount of the derivatives disclosed by P10?
Who signed the filing for P10, Inc.?
